Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1238881.RAklqdA9_c4AwVaFmuPZqDHvTqHZR73trjW__UV-_mktA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1238881.RAklqdA9_c4AwVaFmuPZqDHvTqHZR73trjW__UV-_mktA130_assertion type Assertion NP1238881.RAklqdA9_c4AwVaFmuPZqDHvTqHZR73trjW__UV-_mktA130_head.
- NP1238881.RAklqdA9_c4AwVaFmuPZqDHvTqHZR73trjW__UV-_mktA130_assertion description "[Hence, strategies that prevent GLP-1 degradation or activate the GLP-1 receptor are used to treat patients with type 2 diabetes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1238881.RAklqdA9_c4AwVaFmuPZqDHvTqHZR73trjW__UV-_mktA130_provenance.
- NP1238881.RAklqdA9_c4AwVaFmuPZqDHvTqHZR73trjW__UV-_mktA130_assertion evidence source_evidence_literature NP1238881.RAklqdA9_c4AwVaFmuPZqDHvTqHZR73trjW__UV-_mktA130_provenance.
- NP1238881.RAklqdA9_c4AwVaFmuPZqDHvTqHZR73trjW__UV-_mktA130_assertion SIO_000772 25412624 NP1238881.RAklqdA9_c4AwVaFmuPZqDHvTqHZR73trjW__UV-_mktA130_provenance.
- NP1238881.RAklqdA9_c4AwVaFmuPZqDHvTqHZR73trjW__UV-_mktA130_assertion wasDerivedFrom befree-2016 NP1238881.RAklqdA9_c4AwVaFmuPZqDHvTqHZR73trjW__UV-_mktA130_provenance.
- NP1238881.RAklqdA9_c4AwVaFmuPZqDHvTqHZR73trjW__UV-_mktA130_assertion wasGeneratedBy ECO_0000203 NP1238881.RAklqdA9_c4AwVaFmuPZqDHvTqHZR73trjW__UV-_mktA130_provenance.